Recordati Industria Chimica e Farmaceutica SpA 2021 AR2
The report highlights Recordati's strong performance in 2021, achieving a revenue of ‐1,580.1 million and integrating ESG practices across its operations. The company successfully expanded its rare disease portfolio through the acquisition of EUSA Pharma and the licensing of Eligard. On the environmental front, Recordati achieved its target of purchasing 100% renewable electricity for its European production sites. Additionally, the group demonstrated social responsibility by donating ‐2.5 million to local communities and maintaining a strong focus on employee health and safety during the pandemic.
Company: Recordati Industria Chimica e Farmaceutica SpA
Sector: Manufacturing
Country: Italy
Year: 2021
Type: AR2
Pages: 260
Recordati Industria Chimica e Farmaceutica SpA
The report highlights Recordati's strong performance in 2021, achieving a revenue of ‐1,580.1 million and integrating ESG practices across its operations. The company successfully expanded its rare disease portfolio through the acquisition of EUSA Pharma and the licensing of Eligard. On the environmental front, Recordati achieved its target of purchasing 100% renewable electricity for its European production sites. Additionally, the group demonstrated social responsibility by donating ‐2.5 million to local communities and maintaining a strong focus on employee health and safety during the pandemic.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees